Marinol proposed for Alzheimer’s patients
Unimed Pharmaceuticals in Buffalo Grove, IL, has recruited a panel of Alzheimer’s disease researchers to plan and oversee the company’s Phase II trials aimed at a new indication for Mari-nol (dronabinol). The trials will attempt to gauge Marinol’s effectiveness on behavioral patterns associated with the disease. Made up largely of physicians from New York University, Harvard, the University of Pennsylvania, and Johns Hopkins, the oversight panel also includes representation from Veterans Affairs hospitals and the Geriatric Research Education Clinical Center at Boston University. t
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content